10-KPeriod: FY2009

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2009

Filed February 26, 2010For Securities:BSX

Summary

Boston Scientific Corporation's 2009 10-K filing paints a picture of a company navigating a challenging economic environment while making strategic moves. The report highlights efforts to manage costs and streamline operations, crucial for maintaining profitability in a competitive medical device market. Investors should note the company's focus on innovation and product development, which are key drivers for future growth. While specific financial figures from the provided table of contents are limited, the structure of the report suggests a comprehensive review of the company's performance, risks, and strategic direction. The filing also underscores the importance of regulatory compliance and legal proceedings, which can significantly impact financial performance and investor confidence. The inclusion of various agreements and stipulations, such as a Plea Agreement and Corporate Integrity Agreement, indicates a proactive approach to addressing past issues. Investors will want to pay close attention to the Management's Discussion and Analysis (MD&A) and the Financial Statements for a deeper understanding of the company's financial health and operational strategies.

Financial Highlights

47 data points
Beta

Revenue

$8.19B

68.5% Gross Margin

Net Income

-$1.02B

-12.5% Net Margin

EPS (Diluted)

$-0.68

Total Assets

$25.18B

Cash & Equivalents

$864.00M

Free Cash Flow

$523.00M

Financial Statements
Beta
Revenue$8.19B
Cost of Revenue$2.58B
Gross Profit$5.61B
SG&A Expenses$2.63B
Operating Expenses$6.51B
Operating Income-$894.00M
Interest Expense$407.00M
Net Income-$1.02B
EPS (Basic)$-0.68
EPS (Diluted)$-0.68
Shares Outstanding (Basic)1.51B
Shares Outstanding (Diluted)1.51B

Key Highlights

  • 1The company is filing its annual report for the fiscal year ending December 30, 2009, providing a look back at its performance and strategic initiatives.
  • 2The report structure indicates a detailed examination of the company's business, including its products, services, and market position.
  • 3Significant emphasis is placed on Risk Factors, suggesting that management is aware of and actively addressing potential challenges.
  • 4The filing includes discussions on legal proceedings and regulatory matters, such as a Plea Agreement and Corporate Integrity Agreement, pointing to ongoing compliance efforts.
  • 5Investors can expect a thorough review of the company's financial condition and results of operations within the Management's Discussion and Analysis (MD&A) section.
  • 6Details on equity, related stockholder matters, and issuer purchases of equity securities are presented, offering insights into shareholder value and capital management.
  • 7The report provides selected financial data and full financial statements, which are critical for assessing the company's financial health.

Frequently Asked Questions

While the provided table of contents does not detail specific business segments, Item 1. BUSINESS typically outlines the company's operational divisions, product lines (such as cardiovascular, neuromodulation, and endoscopy), and the markets they serve. Investors should refer to the full 10-K filing for a comprehensive breakdown of each segment's contribution to revenue and profitability.

Item 1A. RISK FACTORS is where the company discloses potential risks. These could include market competition, regulatory hurdles, product development challenges, reimbursement issues, economic downturns, and potential litigation. The filing aims to inform investors about these risks and how the company plans to mitigate them.

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS and Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA will contain the detailed financial performance. Investors should look for trends in revenue growth, gross margins, operating expenses, net income, and cash flow from operations to understand the company's financial health and profitability for the fiscal year 2009.

The inclusion of a Plea Agreement and a Corporate Integrity Agreement in the exhibits suggests that Boston Scientific has been involved in significant legal and compliance matters. Item 3. LEGAL PROCEEDINGS and discussions within the MD&A would provide further details on these matters and their potential financial or operational impact.